ReviewMolecular biology reports2026
Integrating single-cell RNA sequencing with multi-omics to decode disease microenvironments.
Review in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Cell-based therapies of autoimmune diseases in the context of artificial intelligence development.Clinical and experimental medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cellular heterogeneity underpins the complexity of human development and disease, as cells with the same genome exhibit distinct transcriptomic profiles that define their identity, state, and function. Traditional bulk RNA sequencing obscures this heterogeneity by averaging gene expression across mixed cell populations, limiting its ability to resolve rare or disease-associated cell types. Single-cell RNA sequencing (scRNA-seq) has emerged as a powerful technology enabling high-resolution transcriptomic profiling of thousands of individual cells in a single run. Widely adopted platforms, such as the 10x Genomics Chromium system, have accelerated large-scale single-cell studies through their scalability and robust barcoding strategies. Recent advances integrating scRNA-seq with multi-omics approaches, including epigenomics, spatial transcriptomics, and temporal profiling, have further enhanced our understanding of cellular interactions and disease mechanisms. In parallel, artificial intelligence-driven methods, including deep learning and graph-based models, have improved data denoising, clustering, and cell-type annotation. Despite these advances, technical noise, dropout events, and computational challenges remain. This review highlights the integration of single-cell RNA sequencing with multi-omics to decode disease microenvironments.
Indexed as
Identifiers
42377616What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.